Dianhydrogalactitol is under clinical development by Kintara Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dianhydrogalactitol’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 17 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dianhydrogalactitol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dianhydrogalactitol overview

Dianhydrogalactitol (VAL-083/Dag) is under development for the treatment of MGMT-unmethylated GBM, diffuse intrinsic pontine glioma, bevacizumab-naive recurrent glioblastoma multiforme, medulloblastoma, high-grade glioma, relapsed and refractory non-small cell lung cancer, cervical cancer, ovarian cancers, brain tumour and other solid tumours (bladder cancer and head and neck cancer). It is formulated as the injection for intravenous administration. It was under development for recurrent glioblastoma multiforme (GBM), gliosarcoma.

Kintara Therapeutics overview

Kintara Therapeutics (DelMar) formerly DelMar Pharmaceuticals Inc, is a clinical stage drug development bio pharmaceutical company. It is engaged in the development and commercialization of new cancer therapies. The company offers VAL-083, a small molecule chemotherapy used for the treatment of refractory glioblastoma multiforme(GMB) of brain cancer. Kintara also explores VAL-083 as a therapy for solid tumors and front-line GBM including ovarian cancer and non-small cell lung cancer (NSCLC). The company offers its produts and services to lung cancer, ovarian cancer, chronic myeloid leukemia, brain cancers, and lung cancer. Kintara provides warrants services, pre-clinical testing, and clinical trials, among others. It also conducts research and development on cancer indications. It has operations in the US and Canada. Kintara Pharmaceuticals is headquartered in San Diego, California, United States.

Quick View Dianhydrogalactitol LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Dianhydrogalactitol
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.